Press Release

greenovation Biotech GmbH and Biomeva GmbH sign Development, Manufacturing and Supply Agreement for GMP production of a protein with a novel expression platform

Freiburg and Heidelberg, May 6, 2013 – greenovation Biotech GmbH and Biomeva GmbH are pleased to announce the cooperation for the production of a biopharmaceutical protein to treat Fabry disease in the novel and innovative BryoMaster™ moss expression system.

A new dedicated Good Manufacturing Practices (GMP) production area is currently furnished at Biomeva. The first GMP product alpha-Galactosidase for greenovation's Phase I/II clinical trial study in Fabry disease will be available by the end of 2013.

Large scale production will be performed in certified, wave-type disposable bag reactors. The product will be fully characterized physicochemically and biologically in cooperation with a GMP certified analytic laboratory.

The production platform is based on bryotechnology (bryophytes = mosses), developed by greenovation. In this process mosses are genetically modified in a way that enables them to reproduce exactly the desired protein according to a given blueprint.

The technology offers considerable economic advantages over animal derived expression systems due to the absence of animal derived components, an approved absence of viral and other zoonotic pathogens and the extraordinary homogeneity of products. BryoMaster™-products additionally benefit from a high initial purity through secretion into the culture supernatant.

"We are pleased to start this partnership with Biomeva in bringing the greenovation technology from the lab scale towards industrial GMP production scale", emphasized Dr. Frischmuth the CEO of greenovation.

"I am excited that greenovation has selected Biomeva as GMP manufacturer for their new production technology. We look forward to expanding our service portfolio by *going green*" says Dr. Thomas Pultar, CEO of Biomeva.

greenovation Biotech GmbH

greenovation Biotech GmbH is a biopharmaceutical company offering development and production of complex proteins for the pharmaceutical market as well as for in vitro diagnostics (IVD) and research market employing its proprietary BryoTechnology™.

greenovation is closely associated with PANATecs GmbH, a GMP certified analytic laboratory for CMC, product quality and comparability studies. Protein modifications are in particular glyco-designed products for e.g. enhanced antibody dependent cellular cytotoxicity (ADCC), enhanced mannose-glycosylation, glyco-phosphorylation, etc.

greenovation has two pre-clinical programs in the areas of oral diseases (*growth factor FGF7/KGF*) and enzyme replacement therapies (*Fabry* and *Gaucher*) under development. The alpha-Galactosidase replacement clinical trial phase I/II will start in Spring 2014.

Biomeva GmbH

Biomeva GmbH is a reliable and experienced contract manufacturing organization (CMO) in the biopharmaceutical industry and dedicated to meeting the manufacturing needs for the production of microbially and plant cell culture expressed protein products.

Since 1993, BIOMEVA has been producing more than 400 batches of GMP-compliant material for pharmaceutical and biotech companies. Partners benefit from BIOMEVA's track-proven operational expertise in the transfer, development, scale-up and validation of GMP processes.

Biomeva's state-of-the-art GMP production facility and extensive technical expertise are recognized worldwide and provide the necessary support for regulatory approval.

Biomeva is privately owned and located in Heidelberg, Germany.

For more information on greenovation and Biomeva, please contact us:

Manon Bartusel, Tel. +49 (0)761 470 99 0
e-mail mbartusel@greenovation.com
web www.greenovation.com

Dr. Thomas Pultar, Tel. +49 (0)6221 9026 0
e-mail t.pultar@biomeva.com
web www.biomeva.com